| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Fatty acid oxidation pathways are the primary target. This compound is classified as a fatty acid oxidation inhibitor, and it is specifically found to inhibit fatty acid oxidation in biological systems.
|
|---|---|
| ln Vitro |
In cell-free assays, cis-7,10,13,16-Docosatetraenoic acid methyl ester acts as an inhibitor of fatty acid oxidation. Its activity can be measured by its ability to decrease the oxidation rate of fatty acid substrates in enzymatic assays.
|
| ln Vivo |
There is no specific in vivo activity data available for this compound. As a fatty acid oxidation inhibitor found naturally in oregano, it may have applications in studying metabolic regulation of energy homeostasis in animal models.
|
| Enzyme Assay |
There is no specific enzyme/receptor binding protocol for this compound. A general protocol for testing fatty acid oxidation inhibitors involves incubating the compound (e.g., 1-50 uM) with isolated mitochondria or cell lysates in the presence of a radiolabeled fatty acid substrate (e.g., [3H]palmitate), and measuring the production of [3H]water.
|
| Cell Assay |
There is no specific cell-based protocol for this compound. A general protocol would involve treating cells (e.g., hepatocytes or myocytes) with cis-7,10,13,16-Docosatetraenoic acid methyl ester (e.g., 10-100 uM) for 1-24 hours, then assessing fatty acid oxidation rates by measuring the conversion of radiolabeled fatty acids to CO2 or acid-soluble metabolites.
|
| Animal Protocol |
There is no standard in vivo protocol for this compound. A general research protocol would involve administering the compound intraperitoneally (e.g., 10-50 mg/kg) or orally to animal models and measuring its effects on fatty acid oxidation in tissues such as liver or skeletal muscle.
|
| ADME/Pharmacokinetics |
General PK properties for this compound are not applicable for its use as a research reagent. As a highly lipophilic methyl ester, it would require formulation in lipids or detergents for in vivo administration.
|
| Toxicity/Toxicokinetics |
General toxicity for this fatty acid oxidation inhibitor is considered low at experimental doses. No specific toxicity data is available. Standard safety precautions for handling lipid-soluble compounds should be observed.
|
| Additional Infomation |
cis-7,10,13,16-Docosatetraenoic acid methyl ester is a naturally occurring fatty acid derivative found in oregano essential oils. It is used as a biochemical tool to study the role of fatty acid oxidation in metabolic diseases, including obesity, diabetes, and cardiovascular disorders. This product is for research use only.
|
| Molecular Formula |
C23H38O2
|
|---|---|
| Molecular Weight |
346.55
|
| Exact Mass |
346.287
|
| CAS # |
13487-42-8
|
| PubChem CID |
12823768
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
432.1±24.0 °C at 760 mmHg
|
| Flash Point |
99.2±21.2 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.485
|
| LogP |
8.41
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
25
|
| Complexity |
402
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC
|
| InChi Key |
ABGHYAFHPINIHF-ZKWNWVNESA-N
|
| InChi Code |
InChI=1S/C23H38O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23(24)25-2/h7-8,10-11,13-14,16-17H,3-6,9,12,15,18-22H2,1-2H3/b8-7-,11-10-,14-13-,17-16-
|
| Chemical Name |
methyl (7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8856 mL | 14.4279 mL | 28.8559 mL | |
| 5 mM | 0.5771 mL | 2.8856 mL | 5.7712 mL | |
| 10 mM | 0.2886 mL | 1.4428 mL | 2.8856 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
